Document:

ex10_1.htm

EXHIBIT 10.1

Product Development and Supply Agreement

Between

Lacey Manufacturing Company,

a Division of Precision Engineered Products, LLC

1146 Barnum Avenue, Bridgeport, Connecticut 06610

(Also referred to as “LACEY”)

and

Discovery Laboratories, Inc.

2600 Kelly Road

Warrington, Pennsylvania 18976

(Also referred to as “DSCO”)

 

February 1, 2012

  

  

  

 

AGREEMENT

This Product Development and Supply Agreement (“Agreement”) between Lacey Manufacturing Company, a Division of Precision Engineered Products, LLC ( “PEP”), with offices at 1146 Barnum Avenue, Bridgeport, Connecticut 06610 (“LACEY”) and Discovery Laboratories, Inc., with offices at 2600 Kelly Road, Warrington, Pennsylvania 18976 (“DSCO”) is effective as of February 1, 2012 (the “Effective Date”).

Background

LACEY is a full service, vertically integrated  ISO 9001/2008, 13485/2003 Medical Certified Contract Manufacturer of finished assemblies, subassemblies and precision components that provides quality assurance, engineering, metal stamping, injection molding, and assembly services for the Medical Device, Commercial and Bearing Markets.

DSCO is a specialty biotechnology company focused on improving the standard of care for the treatment of respiratory diseases.  DSCO is developing its proprietary (i) KL4 surfactant technology, and (ii) drug delivery technologies, including its capillary aerosolization technology and novel ventilator circuit / patient interface connectors.  In the second half of 2010, DSCO determined that there may be a commercial market for its ventilator circuit / patient interface connectors, if offered as stand-alone medical device products, and is planning to market two versions of the connectors under the trademarks AFECTAIR® and AFECTAIR® DUO (the “AFECTAIR Devices”).

From and after November 24, 2010 (“Initial Contact Date”), DSCO and LACEY have engaged in discussions and activities (collectively, “Preparatory Activities”) concerning the potential manufacture of the AFECTAIR Devices.  Preparatory Activities have included, among other things, discussions concerning the Design of the AFECTAIR Devices, changes to the Design intended to improve Manufacturing efficiency and reliability, and development of drawings and Specifications intended to support Manufacturing.  The Parties are entering into this Agreement to advance their activities to the Manufacturing phase.

Introduction

 

	
1.

	
Purpose.  This Agreement relates to the development and Manufacture of AFECTAIR Devices, as described in Appendix A (the “Program”) and in accordance with the Quality Agreement, which will appended to this Agreement  as Appendix B (the “Quality Agreement”) prior to the initiation of commercial production, and any applicable Purchase Order issued under this Agreement.

	
2.

	
Term. Subject to Section 30, this Agreement will remain effective for a period of three years from the date of the first production Purchase Order for Manufacture of commercially saleable AFECTAIR Devices, or four years from the Effective Date, whichever is shorter (the “Term”).  The Term may be extended by written agreement of the Parties.

	
3.

	
Definitions.  If not otherwise defined in this Agreement, the terms presented in bold type shall have the meanings set forth in this Section 3.  Unless otherwise indicated, references to Sections refer to Sections in this Agreement and references to Sections in the accompanying Appendices to this Agreement refer to each such Appendix, as applicable.  Unless otherwise defined, the defined terms in this Agreement and the Appendices attached to this Agreement have the following meanings:

 

  

Page 1 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	 	
3.1. 

	
“AFECTAIR” isDSCO’s trademark registered in the US Patent and Trademark Office for a medical device intended to simplify delivery of aerosolized medication to patients requiring positive pressure ventilatory support as described in the International Patent Publication WO 2009/117422 and US Patent Application Serial Number 12/922981.

	 	
3.2. 

	
“AFECTAIR DUO” is DSCO’s trademark for a medical device combined with a delivery circuit as described in the International Patent Publication WO 2009/117422 and US Patent Application Serial Number 12/922981.

	 	
3.3. 

	
“AFECTAIR Devices” means either or both of the AFECTAIR and AFECTAIR DUO medical devices.

	 	
3.4. 

	
“Affiliate” shall mean any individual, firm, corporation or other legal entity that   directly or indirectly controls, is controlled by, or is under common control with, a Party.  As used in the preceding sentence, “control” means possession, whether direct or indirect, of the power to direct or cause the direction of the management and policies of such entity, whether pursuant to the ownership of voting securities, by contract or otherwise.  For the purposes of this Agreement, LACEY and Precision Engineered Products, LLC are considered Affiliates with respect to each other.

	 	
3.5. 

	
“Agreement” means this Product Development and Supply Agreement, including the Appendixes, Schedules and Addendums attached hereto, and the Quality Agreement, and includes all Purchase Orders issued pursuant to this Agreement, as each may be amended from time to time.

	 	
3.6. 

	
“Confidential Information” has the meaning set forth in the Mutual Confidential Disclosure Agreement dated November 24, 2010, between DSCO and LACEY.

	 	
3.7. 

	
“Days” means business days, unless otherwise noted in a specific instance.

	 	
3.8. 

	
“Design” means activities related to design of AFECTAIR Devices, changes to the design and drawings, including without limitation, designing a device to be Manufactured to contain a single part or multiple parts.

	 	
3.9. 

	
“DSCO Improvements” has the meaning set forth in Section 7.2.2.

	 	
3.10. 

	
“DSCO Representative” means the individual(s) designated to receive notices related to the Manufacturing operations and regulatory developments.  DSCO will notify LACEY of the name and address of its representative within five Days after the Effective Date.

	 	
3.11. 

	
“Equipment” has the meaning set forth in Section 5. 2 and Appendix A-2, as the same may be amended from time to time.

	 	
3.12. 

	
“EU” means the European Union and includes at a minimum the following countries: United Kingdom, Germany, France, Italy, and Spain.

	 	
3.13. 

	
“FDA” means U.S. Food and Drug Administration.

	 	
3.14. 

	
“FDC Act” means the Federal Food, Drug, and Cosmetic Act, as amended.

	 	
3.15. 

	
“Good Manufacturing Practices” or “GMP” means current good manufacturing practices, as specified in regulations promulgated from time to time by the FDA in its Quality System Regulations, and comparable regulations by other international Regulatory Authorities (e.g., EMA) for the manufacture and testing of pharmaceutical products.

 

  

Page 2 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	 	
3.16. 

	
“Initial Contact Date” has the meaning set forth in the Background to the Agreement.

	 	
3.17. 

	
“Intellectual Property” means all patents, patent applications, copyrights, trademarks, trade names, trade secrets, know-how, service marks, licenses and other intellectual property rights of a Party, that may be secured in any place under Laws now or hereafter in effect.

	 	
3.18. 

	
“Invention” means any new or improved apparatus, process, information, product, invention, discovery, idea, suggestion, material, data, equipment, design, circuit component, drawing, tooling, prototype, report, computer software, documentation or other Intellectual Property or know-how (whether or not patentable) discovered, produced, conceived, created or reduced to practice by either or both Parties (or their Affiliates, sublicensees, subcontractors, successors or assigns).

	 	
3.19. 

	
“ISO 13485” means the International Organization of Standardization’s standard that represents the requirements for a comprehensive quality management system for the design and development, manufacture, installation and servicing of medical devices.

	 	
3.20. 

	
“JOINT Improvements” has the meaning set forth in Section 7.2.3.

	 	
3.21. 

	
“Labeling” means all labels and other written, printed, or graphic material affixed to or accompanying any AFECTAIR Devices or any containers of AFECTAIR Devices or wrappers accompanying such AFECTAIR Devices (e.g., instruction sheets, package inserts).

	 	
3.22. 

	
“LACEY Improvements” has the meaning set forth in Section 7.2.1.

	 	
3.23. 

	
“LACEY Representative” means the individual(s) designated to receive notices related to the Manufacturing operations and regulatory developments.  LACEY will notify DSCO of the name and address of its representative within five (5) Days after the Effective Date.

	 	
3.24. 

	
“Laws” means all applicable laws, statutes, rules, regulations, ordinances, and pronouncements of law of any foreign, federal, state, or local government.

	 	
3.25. 

	
“Manufacture” and “Manufacturing” means the manufacturing, processing, holding, testing, Labeling, and packaging of AFECTAIR Devices and includes all related activities other than Design, including without limitation, purchase, storage and inspection of raw materials/components through molding, assembly, in-process inspections, storage of in-process assemblies, Labeling, packaging, final inspection and storage and handling of finished package product.

	 	
3.26. 

	
“Party” means DSCO or LACEY and, when used in the plural, means both DSCO and LACEY, or their respective transferees.

	 	
3.27. 

	
“Preparatory Activities” has the meaning set forth in the Background Section of this Agreement.

	 	
3.28. 

	
“Program” has the meaning set forth in Section 1 of this Agreement.

	 	
3.29. 

	
“Program-related Intellectual Property” has the meaning set forth in Section 7.2.4.

	 	
3.30. 

	
“Purchase Order” means a DSCO purchase order issued pursuant to this Agreement providing for LACEY Services, which has been executed by both Parties and contains the material terms of the Services, including either the LACEY proposal for, or a description of, the Services being authorized thereunder, timing, pricing, and other requirements, restrictions or agreements of the Parties related thereto.  “Purchase Order” includes a DSCO purchase order for production supply as defined in Section 8.4.  All Purchase Orders shall be in US dollars.

 

  

Page 3 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	 	
3.31. 

	
“Regulatory Authority” means any applicable federal, state, local, or foreign regulatory agency, department, bureau, or other governmental agency (including a court of competent jurisdiction) and includes for the purposes of this Agreement an ISO Certified Body.

	 	
3.32. 

	
“Quality Agreement” has the meaning set forth in Section 1.

	 	
3.33. 

	
“Quality System Regulation” or “QSR” means the FDA’s quality system requirements applicable to manufacturers of finished devices, codified at 21 C.F.R. Part 820.

	 	
3.34. 

	
“Representatives” means a Party’s directors, officers, employees, consultants, attorneys, accountants, advisors, Affiliates and agents and other parties who may receive Confidential Information in furtherance of the Program.

	 	
3.35. 

	
“SEC” means the U.S. Securities and Exchange Commission.

	 	
3.36. 

	
“Services” has the meaning set forth in Section 4 of this Agreement.

	 	
3.37. 

	
“Specifications” means the specifications for each of the AFECTAIR Devices as set forth in each Purchase Order and as described in Section 12.1.

	 	
3.38. 

	
“Term” has the meaning set forth in Section 2.

	 	
3.39. 

	
“US” means United States of America.

Development Agreement

	
4.

	
LACEY’s development activities under this Agreement (the “Services”) include providing regulatory, planning, and development support for the introduction of the AFECTAIR Devices for commercial distribution in the US and/or EU, Manufacture of AFECTAIR Devices, and such other activities related thereto as provided in this Agreement and in any Purchase Order issued under this Agreement.

	
5.

	
Development and qualification activities from and after the date of this Agreement will be quoted based on identified deliverables and incorporated into a Purchase Order.

	 	
5.1. 

	
The terms of aPurchase Order shall not be subject to change, except as agreed by the Parties.  If the scope of Services in a Purchase Order is expanded or otherwise changed, LACEY shall have the opportunity to revise the quotation.  If any such revised quotation is not acceptable to DSCO, DSCO may determine to cease the activities and terminate such Purchase Order, in which event LACEY shall cease its activities under such Purchase Order as promptly as possible and DSCO shall pay LACEY for the Services provided prior to termination.

	 	
5.2. 

	
LACEY is authorized to purchase on DSCO’S behalf the Equipment (the “Equipment”) listed in Appendix A-2 which is specially required for the performance of the Services; provided that (i) the Parties enter into a Purchase Order detailing the Equipment as and when ordered, and (ii) an Equipment Purchase Order Addendum is entered into by the Parties in connection with each Equipment Purchase Order in the form attached hereto as Addendum I to Schedule A.  DSCO shall issue Purchase Orders to LACEY at quoted prices for the purchase and installation of such Equipment.

	
6.

	
DSCO has responsibility for the following with regard to the AFECTAIR Devices and as reflected in Section 12.1:

	 	
6.1. 

	
Devising and supplying productSpecifications;

 

  

Page 4 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	 	
6.2. 

	
Devising and supplying product acceptance criteria, including defect identification and a sampling plan;

	 	
6.3. 

	
Approval of and responsibility for an overallAFECTAIR Devices validation strategy;

	 	
6.4. 

	
Approval of protocols for IQ/OQ/PQ builds to support the process validation strategy to be provided byLACEY; and

	 	
6.5. 

	
Design Control and Device Master record approval in accordance withFDA GMP and ISO13485 requirements.

Intellectual Property

	
7.

	
The funding of all Intellectual Property, research & development, regulatory affairs, clinical activities, if any, and claims of equivalency to other products related to the AFECTAIR Devices will be the responsibility of  DSCO, except as provided in Section 7.2.1.

	 	
7.1. 

	
Each ofDSCO and LACEY, as applicable, shall own

	 	
7.1.1.

	
[***]

	 	
7.1.2.

	
[***]

	 	
7.2. 

	
With respect to allInventions conceived, created, and reduced to practice after the Initial Contact Date solely by or on behalf of either Party or jointly by or on behalf of the Parties, such Inventions shall be owned as follows:

	 	
7.2.1.

	
LACEY shall have the exclusive ownership of any [***] (collectively “LACEY Improvements”).  LACEY shall assume full financial responsibility over Lacey Improvements.

	 	
7.2.2.

	
DSCO shall have the exclusive ownership of any [***], excluding LACEY Improvements and including, without limitation, [***] ,(y) DSCO’s [***]  (collectively “DSCO Improvements”). DSCO shall assume full financial responsibility for DSCO Improvements.

	 	
7.2.3.

	
DSCO shall have the exclusive ownership of any [***] (collectively “Joint Improvements”).  [***] shall assume full financial responsibility over JOINT Improvements.

	 	
7.2.4.

	
For the purposes of this Agreement, “Program-related Intellectual Property” includes DSCO Improvements, LACEY Improvements, and Joint Improvements.

	 	
7.3. 

	
During theTerm and solely for the purposes of performing their respective obligations under this Agreement, each of DSCO and LACEY hereby grants to the other Party a non-exclusive, non-transferable, royalty-free and limited license to use the Program-related Intellectual Property. The rights granted under this Section 7.3 shall expire immediately upon expiration or termination of this Agreement.

	 	
7.4. 

	
EachParty shall maintain records in sufficient detail and in good scientific manner appropriate for patent prosecution purposes to reflect properly all work done and results achieved in conducting its work hereunder, and shall respond to reasonable requests of the other Party for information regarding Program-related Intellectual Property in which the other Party has an ownership interest.

	 	
7.5. 

	
In the event thatLACEY shall determine to prosecute a patent relating to LACEY Improvements, as soon as practicable prior to any contemplated filing, LACEY shall submit a substantially completed draft of the applicable patent to DSCO for review and comment, which comments shall be considered in good faith.  Should DSCO reasonably and in good faith, based on an opinion of counsel (including internal counsel), a copy of which will be supplied to LACEY, object to such proposed filing on the grounds that it would detrimentally affect, or would have an unreasonable risk of detrimentally affecting the confidentiality of DSCO’s Intellectual Property rights (including, without limitation, its trade secrets and know-how), then DSCO shall be entitled to require LACEY to amend its filing to the extent necessary to protect DSCO’s Intellectual Property rights.

 

  

Page 5 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	 	
7.6. 

	
During theTerm, LACEY shall mark or have marked all finished goods containers or packages of AFECTAIR Devices with appropriate patent numbers and notices that DSCO will provide.

Supply Agreement

 

	
8.

	
Pricing.

	 	
8.1. 

	
Until such time as one or both the AFECTAIR Devices Manufactured by LACEY for DSCO reach steady-state Manufacture and a price list is created, unit transfer pricing for all products Manufactured by LACEY for DSCO will be established by written individual quotations that will be incorporated into a Purchase Order.  The Parties agree that an initial indicative price list based on currently defined DSCO specification is reflected in LACEY’s proposal dated August 12, 2011.  With the consent of DSCO, which shall not be unreasonably withheld, the pricing to be incorporated into any Purchase Order shall be subject to amendment as agreed by the Parties based on changes in the Specifications and cost of raw materials, etc.

	 	
8.2. 

	
LACEY will be responsible for all production aspects of the  AFECTAIR Device Program, including supplier management for tooling, raw materials, purchased and manufactured components, assembly, and packaging.

	 	
8.3. 

	
DSCO agrees to supply LACEY monthly with a rolling six-month forecast for the production of AFECTAIR Devices.  DSCO will be financially responsible for materials, work in process, and finished goods conforming to Specifications for [***]

	 	
8.3.1.

	
LACEY will take reasonable care to minimize financial exposure of DSCO as far as is practical based on lead-time requirements.

	 	
8.4. 

	
Purchase Orders for commercial product shall be supplied by DSCO with the following minimum information:

	
  

	
8.4.1.

	
P.O. Number;

	
  

	
8.4.2.

	
Date of P.O.;

	
  

	
8.4.3.

	
Part Number being ordered;

	
  

	
8.4.4.

	
Revision of part number being ordered;

	
  

	
8.4.5.

	
Quantity of part number being ordered;

	
  

	
8.4.6.

	
Requested delivery date;

	
  

	
8.4.7.

	
Delivery address of products;

	
  

	
8.4.8.

	
Product Specification number(s);

	
  

	
8.4.9.

	
Revision of Product Specification(s); and

	
  

	
8.4.10.

	
Other instructions as applicable.

	 	
8.5. 

	
LACEY will supply DSCO with an Order Confirmation accepting the order as specified or identifying any changes required to fulfill the order.

	 	
8.6. 

	
It is understood by bothParties that [***] for DSCO AFECTAIR Devices and that, [***]

	 	
8.7. 

	
All proposals andPurchase Orders shall be denominated in US dollars.

  

Page 6 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

Regulatory Matters

 

	
9.

	
General.  DSCO and LACEY shall each comply in all material respects with all applicable Laws that pertain to the activities for which DSCO and LACEY are each responsible under this Agreement, as described in Appendix A and in accordance with the Quality Agreement.  The termination or expiration of this Agreement shall not relieve either Party of its responsibility to comply in all material respects with any applicable regulatory requirements associated with the AFECTAIR Devices.

	
10.

	
Non-transferability of Duties.  LACEY shall not transfer or assign any of its duties or responsibilities under this Agreement without prior written approval of DSCO.

	
11.

	
Regulatory Approvals; Labeling.  DSCO shall be responsible for compliance with all premarket requirements under Section 510(k) of the FDC Act and the applicable Laws of EU countries, as applicable to the AFECTAIR Devices.  DSCO shall be responsible for obtaining and maintaining premarket notification (510(k)) clearance for AFECTAIR Devices or determining that there is an applicable 510(k) exemption, as required by the FDC Act and its implementing regulations.  DSCO shall be responsible for the design and content of the Labeling of AFECTAIR Devices, and ensuring that the Labeling complies with all applicable Laws, including the FDC Act and its implementing regulations.

	
12.

	
Quality System.

	 	
12.1. 

	
General; QSR Requirements.  DSCO and LACEY shall each operate in substantial compliance with all applicable Laws, including the FDA current good manufacturing practice (cGMP) requirements set forth in the Quality System Regulations.  Each Party shall bear its own costs and expenses related to QSR compliance.  DSCO shall be responsible to finalize Specifications for each AFECTAIR Device, which shall be counter-signed and dated by both Parties and issued by DSCO to LACEY for AFECTAIR Devices inclusion in the LACEY quality system.  The Specifications will contain drawings, raw material and packaging component requirements, and/or product performance requirements as necessary.  The Specifications will bear a version number controlled by DSCO.  The Specifications may only be amended or changed by a writing signed by both Parties, as described in Section 14.1.

	 	
12.2. 

	
Manufacturing Activities.  LACEY shall Manufacture all AFECTAIR Devices in substantial compliance the QSR and ISO 13485 requirements, and the terms and conditions of the Quality Agreement, this Agreement, each applicable Purchase Order, and the Specifications.

	
13.

	
Packaged Product Storage and Shipment: LACEY shall store all finished and packaged AFECTAIR Devices in substantial compliance with all applicable Laws, including the QSR and ISO 13485 requirements, and the terms and conditions of the Quality Agreement, this Agreement, each applicable Purchase Order, and the Specifications.  LACEY will handle and load finished and packaged AFECTAIR Devices onto transport carriers designated by DSCO in conformance with all applicable Laws, including the  QSR and ISO 13485 requirements, and the terms and conditions of the Quality Agreement, this Agreement, each applicable Purchase Order, and the Specifications.  DSCO shall be responsible for the shipment of all finished and packaged AFECTAIR Devices

	
14.

	
Manufacturing Changes.  LACEY shall not make any changes, including the use of non-conforming materials, components, or assemblies used in the Manufacture of the AFECTAIR Devices without documenting the change pursuant to A LACEY engineering document change notice (DCN), which shall not be effective until approved, counter-signed, and dated by a DSCO Representative.  Temporary change notices (TCN) or deviations shall also include the DSCO Representative’s counter-signature and date.  DSCO shall review and respond to documentation submitted by LACEY for review or approval within 5 Days of receipt.

 

  

Page 7 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	 	
14.1. 

	
[***], may make changes to the Design of the AFECTAIR Devices.  Changes to Specifications relating to Manufacture, quality, or other LACEY procedures will require a DSCO Engineering Change Order (ECN) and subsequent LACEY DCN, which shall be counter-signed and dated by both Parties.  Each Party will respond to submitted documentation within 5 Days of receipt.

	
15.

	
Product Review.  LACEY shall provide DSCO with documentation of review and approval of each production lot of finished products prior to their release in the form of a Certificate of Conformity (CoC), in such form as shall be acceptable to both Parties.  Each CoC must be signed and dated by a LACEY Representative and thereafter countersigned and dated by a DSCO Representative within 5 Days of receipt.

	
16.

	
Post-Market Modifications.  Any regulatory filings incident to change(s) in Manufacturing and/or Specifications shall be the responsibility of DSCO.

	
17.

	
Product Returns; Complaints; Adverse Events.

	 	
17.1. 

	
Any investigation, response or other action incident to product returns or complaints and/or adverse events shall be the responsibility ofDSCO.  LACEY shall cooperate  fully with DSCO in investigating and resolving returns or customer complaints concerning the AFECTAIR Devices, and shall take such action to promptly resolve such complaints as may be reasonably requested by DSCO.  The Parties shall establish and implement a system for exchange of complaint and adverse event information sufficient to allow the Parties to comply with all applicable regulations, which shall include appropriate provisions for recording customer complaints relating to AFECTAIR Devices and prompt notice to the other Party of significant and/or potentially reportable adverse events.  Each Party shall provide accurate and timely information about complaints and adverse events to the other Party, when applicable, and shall otherwise cooperatively undertake investigations and provide information and analyses as reasonably requested by the other Party and as necessary to support DSCO’S fulfillment of complaint handling and Medical Device Reporting (MDR) requirements (21 C.F.R. Part 803) requirements.  Each Party shall bear its own costs and expenses in fulfilling its obligations under and in accordance with this Section 17.1.

	 	
17.2. 

	
DSCO shall be responsible to ensure substantial compliance with all applicable Laws pertaining to product returns, complaint handling and the reporting of adverse device events, including FDA’s complaint handling requirements under the QSRs (21 C.F.R. § 820.198) and the MDR.  Both Parties shall cooperate to submit a request to FDA under 21 C.F.R. § 803.19(c) to exempt LACEY from the MDR requirements, and to allow DSCO to satisfy the reporting obligations for both Parties.  Each Party shall bear its own costs and expenses in fulfilling its obligations under and in accordance with this Section 17.2.

	
18.

	
Recalls; Corrections and Removals.  All recall actions will be issued by DSCO.  If LACEY becomes aware of any defect, problem, or adverse condition in any AFECTAIR Devices, LACEY shall promptly notify DSCO.  LACEY shall cooperate fully with DSCO in investigating and resolving any correction, removal or field action.  Each Party shall bear its own cost and expenses of any correction, removal, or field action.  Each Party shall use reasonable efforts to ensure substantial compliance with all applicable Laws pertaining to corrections and removals, including voluntary actions under 21 C.F.R. Part 7 and FDA’s reporting requirements of corrections and removals under 21 C.F.R. Part 806.  Each Party shall provide the other Party with advance copies of all filings to be made with the FDA under this Section 18.

 

  

Page 8 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	
19.

	
Audits and Inspections.

	 	
19.1. 

	
LACEY shall provide DSCO or DSCO’S Representatives reasonable access upon reasonable prior notice to inspect, review, and audit the LACEY facility(ies) where the AFECTAIR Devices are being Manufactured for the purpose of confirming that all AFECTAIR Devices are Manufactured in accordance with applicable Laws and the terms of this Agreement.  In connection with any such inspection, review, or audit, LACEY shall allow DSCO or its Representatives to review and inspect the applicable facility(ies) and records, and to meet with LACEY personnel to discuss whether LACEY’s procedures and record-keeping are compliant with applicable Laws.  Such inspections, reviews, and audits can take place on reasonable notice to LACEY and shall be conducted during normal business hours and in a manner intended to not unreasonably disrupt the normal operations of LACEY.  DSCO may review but not copy LACEY procedure documents.

	 	
19.2. 

	
LACEY shall advise DSCO within one business day if an authorized agent of the FDA or other Regulatory Authority inspects, reviews, or audits LACEY’s manufacturing facility(ies), and/or if the Regulatory Authority requests or requires information or changes that directly pertain to the AFECTAIR Devices or that may negatively impact LACEY’s ability to continue to Manufacture AFECTAIR Devices under this Agreement.  LACEY shall provide DSCO with copies of all correspondence from a Regulatory Authority regarding the inspection, review, or audit of LACEY operations related to the AFECTAIR Devices, which may include, without limitations, facility registration or ISO certification changes or updates, Establishment Inspection Reports, Form FDA 483s, or equivalent forms issued by other Regulatory Authorities, and warning or untitled letters.  DSCO shall have the opportunity to review and comment on LACEY’s written responses to a Regulatory Authority and shall assist LACEY to address any Regulatory Authority inquiry or investigation related to the AFECTAIR Devices.

	 	
19.3. 

	
DSCO shall advise LACEY within one business day if an authorized agent of the FDA or other Regulatory Authority audits the AFECTAIR Devices and/or if the Regulatory Authority or requests or requires information or changes that directly pertain to the Manufacture of AFECTAIR Devices or that may negatively impact LACEY’s ability to continue to Manufacture AFECTAIR Devices under this Agreement.  LACEY shall assist DSCO in responding to an inquiry from a Regulatory Authority, as a result of an inspection, review, or audit of DSCO’s operations related to the AFECTAIR Devices.

	 	
19.4. 

	
EachParty shall notify the other Party if it becomes aware of a pending or existing administrative or government court-initiated action against the Party, including, but not limited to, seizures, injunctions, and criminal prosecution, that may affect the Party’s ability to comply with the terms of this Agreement.

	
20.

	
FDA Debarment Certification.  LACEY represents and warrants that, after due inquiry, it shall not knowingly employ, contract with or retain any person directly or indirectly to perform Services under this Agreement, if such person is debarred by the FDA under 21 USC 335a(k) of the FDA Act or a regulator in the EU under similar Laws.  Upon written request from or on behalf of DSCO, LACEY shall within 5 Days confirm in writing that it has complied with the foregoing obligation.

 

  

Page 9 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

General Terms

 

	
21.

	
Payment.

	 	
21.1. 

	
Payment terms forServices related to AFECTAIR development, qualification and Manufacturing will be included in individual Purchase Orders.  Information on payment, security interest, delivery terms, risk of loss, shipment dates, cancellation, and special orders are included in the terms and conditions set forth on Appendix A-1.

	 	
21.2. 

	
Notwithstanding any other provision of this Section 21, ifDSCO in good faith disputes all or a portion of a LACEY invoice, then DSCO shall pay any undisputed amount and shall promptly provide LACEY a written explanation of the reasons for the dispute and the related amount.  The Parties shall work together in good faith to resolve any dispute within 30 calendar Days.  The time period may be extended by mutual agreement of the Parties.  If the Parties are unable to resolve the dispute, either Party may refer the matter to arbitration in accordance with Section 27.  During the pendency of any dispute, LACEY shall continue to perform Services under this Agreement.

	 	
21.3. 

	
If any term of thisAgreement conflicts with any term of an accepted Purchase Order, the terms set forth in this Agreement shall supersede the conflicting terms in such Purchase Order, except to the extent that such Purchase Order expressly states in a document signed separately by both Parties that they intend to vary the terms of this Agreement as it applies to such Purchase Order.

	
22.

	
Warranties.

	 	
22.1. 

	
LACEY warrants only that the goods delivered hereunder will conform to the Specifications provided by DSCO and will be free from defects in material or workmanship.

	 	
22.2. 

	
There are no other warranties other than those contained in each acknowledgedPurchase Order.

	 	
22.3. 

	
LACEY makes no warranty of merchantability or fitness for purpose of the goods covered by this Agreement.

	
23.

	
Indemnification.

	 	
23.1. 

	
DSCO shall indemnify, defend and hold harmless LACEY, its parents and Affiliates and each of their respective employees, officers, directors and agents (hereinafter “LACEY Indemnified Parties”) from and against any and all damages, liabilities, claims, costs, charges, judgments and expenses (including reasonable attorney’s fees) (collectively “Damages”) that may be sustained, suffered or incurred by LACEY, or LACEY Indemnified Parties arising directly from (1) the breach by DSCO of any warranty, representation, covenant, or agreement made by DSCO in this Agreement; (2) any product liability or personal injury claim by third parties arising from the Design, sale, distribution or indicated use of any product that meets DSCO’S quality requirements and Specifications and is not otherwise defective; and (3) any claim that any product Manufactured by LACEY under this Agreement or the use or sale thereof infringes any patent of any third party, except to the extent that such claim is based on LACEY Intellectual Property or LACEY Improvements.

 

  

Page 10 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	 	
23.2. 

	
LACEY shall indemnify, defend and hold harmless DSCO, its parents and Affiliates and each of their respective employees, officers, directors and agents (hereinafter “DSCO Indemnified Parties”) from and against any and all Damages that may be sustained, suffered or incurred by DSCO or DSCO Indemnified Parties arising directly from (1) the breach by LACEY of any warranty, representation, covenant or agreement made by LACEY in this Agreement – provided that LACEY shall not be liable for any product liability or personal injury claims by third parties arising from the Design, sale, distribution, or indicated use of any product which meets DSCO quality requirements and Specifications and is not otherwise defective; (2) any claim raised by any LACEY employee(s) or other persons against DSCO and DSCO Indemnified Parties in connection with possible injuries suffered when using or servicing any of the DSCO-owned Equipment located on LACEY’s premises, (3) LACEY’s use of the Equipment, (4) any alleged violation of any environmental requirements in the Manufacture of AFECTAIR Devices, and (5) any third-party claim that any product purchased from DSCO made in accordance with LACEY Intellectual Property or LACEY Improvements or the use or sale thereof infringes any patent of any third party.

	 	
23.3. 

	
LACEY shall indemnify DSCO for all claims, demands, suits, or actions which may be asserted against DSCO for any kind of losses related to defects in materials and/or workmanship of the AFECTAIR Devices.

	 	
23.4. 

	
EXCEPT FOR INFRINGEMENT OFINTELLECTUAL PROPERTY RIGHTS OR AS NECESSARY TO SATISFY A THIRD PARTY CLAIM INDEMNIFIED HEREUNDER AND/OR IN THE EVENT OF A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS SET FORTH IN SECTION 28 OF THIS AGREEMENT, UNDER NO CIRCUMSTANCES SHALL LACEY’s TOTAL LIABILITY TO DISCOVERY LABS IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, THE AFECTAIR DEVICES OR ANY SERVICES PROVIDED IN CONNECTION WITH THE AFECTAIR DEVICES, [***].

	 	
23.5. 

	
EXCEPT FOR INFRINGEMENT OFINTELLECTUAL PROPERTY RIGHTS OR AS NECESSARY TO SATISFY A THIRD PARTY CLAIM INDEMNIFIED HEREUNDER AND/OR IN THE EVENT OF A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS SET FORTH IN SECTION 28 OF THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS AGREEMENT OR THE PROGAM CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.  NOTWITHSTANDING THE FOREGOING, DIRECT DAMAGES OF A PARTY WITH RESPECT TO A THIRD PARTY CLAIM SHALL INCLUDE ALL DAMAGES AWARDED TO SUCH THIRD PARTY, INCLUDING ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES.

 

  

Page 11 of 24

  

 

	
24.

	
Procedure for Indemnification.

	 	
24.1. 

	
In the event that any person (an “Indemnified Party”) entitled to indemnification under Section 23 is seeking indemnification, such Indemnified Party shall promptly notify the indemnifying Party (“Indemnitor”) in writing of the claim (and in reasonable detail); provided, however, that failure to give such notification shall not affect the indemnification to be provided hereunder except to the extent Indemnitor shall have been actually prejudiced as a result of such failure.  As a condition to indemnification under this Agreement, Indemnitor, in its sole discretion, may manage and control, at its sole expense, the defense of the claim and its settlement.  The Indemnified Parties shall provide Indemnitor with reasonable assistance and cooperation and all material relevant information to support the defense of any indemnified claim, and Indemnitor shall reimburse the Indemnified Parties for their reasonable out-of-pocket expense incurred in connection with such assistance and cooperation.  Indemnitor shall not accept any settlement which imposes liability not covered by the indemnification provided under this Agreement or imposes any obligation on, or otherwise adversely affects, the LACEY Indemnified Parties or the DSCO Indemnified Parties without the prior written consent of such affected Indemnified Party, as applicable.  Indemnitor shall have no obligation to indemnify the Indemnified Parties in connection with any settlement made without Indemnitor’s written consent.  Except for such assistance and cooperation as may reasonably be requested by Indemnitor, nothing contained in this Section 24 shall require the Indemnified Party to take any action in its own name in defending any claim, action or proceedings; however, the Indemnified Party, at is option and expense, may review and comment on the defense of any claim through its own counsel.  If (i) in the opinion of counsel for the Indemnified Party, representation of the Indemnified Party by the counsel retained by Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnified Party and any other Party represented by such counsel in such proceedings, or (ii) the named parties to any such proceeding (including the impleaded parties) include both Indemnitor and the Indemnified Party, and representation of both Parties by the same counsel would be inappropriate in the opinion of the Indemnified Party’s counsel due to actual or potential differing interests between them; in any such case, one firm of attorneys separate from Indemnitor’s counsel may be retained to represent the Indemnified Party at Indemnitor’s expense.  As the Parties intend complete indemnification, all reasonable attorneys’ fees and expenses incurred by an Indemnified Party in connection with enforcement of Sections 23.1, 23.2, and 23.3 shall also be reimbursed by Indemnitor.

	 	
24.2. 

	
IfLACEY receives a written legal opinion or notification that the Manufacture, sale, or use of AFECTAIR Devices infringe on the proprietary information or patents of a third party, LACEY shall promptly deliver a copy of such opinion or notification to DSCO.  LACEY may discontinue Manufacture of any goods involved in the alleged infringement with prior written notice to DSCO provided that DSCO is given a reasonable period of time to ascertain the legitimacy of such opinion or notice and discuss with LACEY.  In the event DSCO believes (upon the advice of its counsel, including internal counsel) that neither the Manufacture, sale, nor use of AFECTAIR Devices infringe on the proprietary information or patents of such third party, in order to ensure continuous availability of AFECTAIR Devices Manufacture by LACEY, DSCO may notify LACEY that it wishes to continue the Manufacture of AFECTAIR Devices and, in connection therewith, will indemnify LACEY in accordance with Section 23.1.  Upon receipt of such notice, LACEY will continue to Manufacture AFECTAIR Devices.

 

  

Page 12 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	
25.

	
Insurance.

	 	
25.1. 

	
EachParty shall at all times maintain all necessary insurance coverage with sound and reputable independent insurers at commercially reasonable levels of coverage or shall be self insured at levels that are consistent with industry practice, having regard to the nature, type, scope and size of the business it conducts and all its respective activities and obligations under this Agreement, which shall include, at a minimum: (i) comprehensive general liability insurance, including property damage, for injury to persons or damage to property; (ii) workers compensation and employers’ liability coverage with required statutory limits for workers compensation and employers liability limits: (iii) property insurance covering the AFECTAIR Devices, molds and tooling, and DSCO materials and Equipment; and (iv) products liability insurance, which, if the policy is a claims-made policy, includes coverage for a period of at least 10 years after the performance of the Program.   Each Party shall make reasonable commercial efforts to insure that all of its insurance policies shall be issued by “A-rated” insurers as designated by Standard and Poor’s Corporation or A.M. Best.  Each Party shall, upon reasonable request of the other Party, produce satisfactory evidence that all insurance premiums have been paid and kept up to date and are kept in accordance with local insurance laws or regulations from time to time in force, or shall furnish appropriate certificates of insurance showing proof of coverage.  The insurance coverage may be provided through a combination of primary, excess/umbrella or self-insured retention, and shall not serve to operate as a limitation on the recovery of any claim.  Each Party shall include the other Party as a named insured on its policies of insurance, as the other Party’s interests may be affected pursuant to this Agreement.

	 	
25.2. 

	
The requirement for insurance shall not be construed to establish a limit on liability hereunder.  Upon the request of  a Party, the otherParty shall furnish to the requesting Party a certificate of insurance evidencing the coverage provided in this Section 25 as of such date, pursuant to which the insurer agrees to notify such other Party 30 days in advance of any coverage change, nonrenewal or cancellation.  In the case of a coverage change, nonrenewal or cancellation, the affected Party shall provide the other Party with a new certificate of insurance evidencing the coverage provided in this Section 25.

	
26.

	
Force Majeure.

	 	
26.1. 

	
NeitherParty shall be responsible or liable, or deemed in breach hereof, to the extent the performance of its obligations hereunder is delayed or prevented due solely to circumstances beyond the reasonable control and without the fault or negligence of the Party experiencing such impediment to performance (such causes hereinafter called “Force Majeure”).  Such causes may include but shall not be limited to acts of God; unusually severe weather; war; riots; fire; actions or failures to act on the part of governmental authorities which delay or prevent performance; or the Party’s inability despite due diligence to obtain required licenses.  In the event either Party is delayed or rendered unable to perform due to Force Majeure, the affected Party shall give prompt notice of the conditions and the expected duration to the other Party promptly after the occurrence of the cause relied upon, and upon the giving of such notice the obligations of the Party giving the notice will be suspended during the continuance of the Force Majeure for a period [***] or as agreed upon in writing by the Parties.

 

  

Page 13 of 24

  

 

	
27.

	
Arbitration.

	 	
27.1. 

	
Any controversy or claim arising out of or relating to thisAgreement or the validity, inducement or breach thereof, shall be settled by binding arbitration before a single arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) then pertaining, except where the rules conflict with this provision, in which case this provision shall control.  The Parties hereby consent to the jurisdiction of the federal district court for the district in which the arbitration is held for the enforcement of this provision and the entry of judgment on any award rendered hereunder.  Should such court for any reason lack jurisdiction, any court with jurisdiction shall enforce this clause and enter judgment on any award.  The arbitrator shall be an attorney with at least 15-years experience with a law firm, corporate law department, or as a judge in a court of general jurisdiction.  The arbitration shall be held in New York City or such other venue as is agreeable to both Parties.  In rendering the decision, the arbitrator shall apply the substantive law of Connecticut (except where the law conflicts with this clause) except that the interpretation and enforcement of this provision shall be governed by the Federal Arbitration Act.  The arbitrator shall be selected from a panel of qualified arbitrators of AAA.  Within forty five (45) days of initiation of the arbitration, the Parties shall reach agreement upon the procedures to be followed.  Failing such agreement, AAA will design and the Parties shall follow procedures that are reasonably designed to conclude the arbitration within eight (8) months.  Each Party has the right before and during the arbitration to seek and obtain from the appropriate court provisional remedies, including but not limited to, attachment, preliminary injunction and replevin in order to avoid irreparable harm.  THE ARBITRATOR SHALL NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY, MULTIPLIED, CONSEQUENTIAL DAMAGES AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO SEEK SUCH DAMAGES.  NO PARTY MAY OBTAIN PREJUDGMENT INTEREST, ATTORNEYS’ FEES OR COSTS.

	
28.

	
Confidentiality.

	 	
28.1. 

	
EachParty acknowledges and agrees to maintain the confidentiality of all Preparatory Activities and negotiations undertaken in connection with the Program and Services and the other Party’s respective Confidential Information, in each event in accordance with the Mutual Confidential Disclosure Agreement between the Parties, dated as of November 24, 2010 (the “CDA”), which shall survive execution of this Agreement.  DSCO and LACEY hereby agree to amend the CDA by extending the period provided in Section 16 of the CDA for a period ending five (5) years after the date of expiration or earlier termination of this Agreement.  Further, the Parties acknowledge and agree that any future Supply Agreements shall contain mutually agreeable terms and conditions with respect to the Parties’ obligations of confidentiality with regard to Confidential Information on terms substantially similar to the CDA.

	 	
28.2. 

	
NeitherParty shall disclose the terms of this Agreement to a third party, except for legal, financial, accounting or other similar advisors who agree to keep the terms of this Agreement confidential, without the prior written approval of the other Party, or as otherwise required by law.  Furthermore, neither Party will originate any publicity, news release, or other public announcement, written or oral, whether to the public press, to stockholders, or otherwise, relating to this Agreement, to any amendment hereto or to performance hereunder or the existence of an arrangement between the Parties without the prior written approval of the other Party.  However, nothing herein shall prevent a Party from disclosing Confidential Information on a need-to-know basis to an employee of its parent corporation or any other corporation under common ownership and control; providing said employees are informed of the confidential nature of the information and further provided that each Party shall be liable for any violation of the provisions of this Agreement that occur as the result of the conduct of any employee of the parent or any employee of a company under common ownership and control with such Party.

	 	
28.3. 

	
Notwithstanding anything to the contrary in thisAgreement, LACEY acknowledges and agrees that, if DSCO determines in its sole judgment to do so, DSCO may describe the material terms of this Agreement and any future Supply Agreement in any of its reports and filings with the SEC and may file a copy of this Agreement and any future Supply Agreements with the SEC, as well as incorporate the descriptions and this Agreement (and any Supply Agreements) by reference into other SEC filings.  In such event, DSCO will notify LACEY and request that the SEC agree to confidential treatment of sensitive terms contained in this Agreement or any future Supply Agreements to the extent such confidential treatment is reasonably available to DSCO.

 

  

Page 14 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	
29.

	
Asset Management.

	 	
29.1. 

	
DSCO, as owner of the Equipment, molds and tooling, and other capital assets used in the production of the AFECTAIR Devices, will be responsible for the purchase price and the cost of installation, maintenance and other related expenses.  Such assets include but are not limited to the Equipment listed on Appendix A-2, as amended from time to time, purchased by LACEY on DSCO’S behalf.

	 	
29.2. 

	
LACEY shall enter into and attach to each Equipment Purchase Order an Equipment Addendum substantially in the form included in Appendix A-2.  LACEY agrees that it will provide information  concerning its facility as may reasonably be requested by DSCO in order to schedule the DSCO assets located on LACEY’s premises under DSCO’s insurance policies.

	
30.

	
Termination.

	 	
30.1. 

	
DSCO may terminate this Agreement:

	
  

	
30.1.1.

	
Upon [***] to LACEY of plans to discontinue the Program, [***].

	
  

	
30.1.2.

	
If such termination is made [***], upon [***] written notice to LACEY.

	
  

	
30.1.3.

	
upon [***] notice to LACEY if (i) LACEY is unable to Manufacture AFECTAIR Devices substantially in accordance with the terms of an accepted Purchase Order; (ii) [***]; or (iii) if the FDA or other Regulatory Authority revokes, or provides any formal notification that reasonably could be expected to result in revocation of, any registration, certification or authorization that is required or necessary to Manufacture AFECTAIR Devices in accordance with this Agreement, the Quality Agreement or any applicable Purchase Order.

	 	
30.2. 

	
LACEY may terminate this Agreement:

	
  

	
30.2.1.

	
Upon [***] notice of plans to discontinue Manufacture of the AFECTAIR Devices.

	
  

	
30.2.2.

	
For cause, if DSCO fails to make any payment on the due date set forth in an accepted Purchase Order and does not remedy such failure [***].

	 	
30.3. 

	
EitherParty may terminate this Agreement:

	
  

	
30.3.1.

	
upon [***] notice to the other Party if the Parties, after a good faith effort, are unable to agree on [***].  For the purposes of this Section 30.3.1, “good faith effort” means that the Parties have negotiated in good faith and have escalated any irresolvable issues to their respective Presidents.

	
  

	
30.3.2.

	
upon [***] notice to the other Party, if such other Party is in breach of any material obligation under this Agreement and such breach is not cured [***]; or

	
  

	
30.3.3.

	
immediately, if the other Party (i) ceases for any reason to carry on business, dissolves, liquidates, winds up, or files or is petitioned into bankruptcy (and any such voluntary petition is not dismissed [***]), liquidation, rehabilitation or dissolution or (ii) becomes insolvent or fails generally to pay its debts or obligations or (iii) a petition is filed seeking the appointment of or the taking possession by a receiver, custodian, trustee or similar official.

 

  

Page 15 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	
31.

	
Effects of Termination.  Upon termination of this Agreement:

	 	
31.1. 

	
LACEY will cooperate and provide reasonable assistance to DSCO to transfer (at DSCO’S expense) all Equipment, inventory and materials to any successor site or to such other location that DSCO may designate in writing.  DSCO will issue Purchase Orders to LACEY to cover all reasonable costs related to the transfer and return of the Equipment, inventory and materials.  Unless otherwise agreed, such reimbursement costs shall be consistent with the costs reflected in the two most-recent accepted Purchase Orders.  [***].

	 	
31.2. 

	
EachParty will return to the other Party or certify in writing to the other Party that it has destroyed all documents and other tangible items it or its employees or agents have received or created pursuant to this Agreement pertaining, referring or relating to the Confidential Information of the other Party, except that each Party may retain one (1) complete copy of Confidential Information for archival purposes to assure compliance with this Agreement

	
32.

	
Amendments.  Amendments, modifications, and additions to this Agreement must be made in writing and must be signed by authorized officers of the respective Parties hereto.  No invoice, quotation, acknowledgment, Purchase Order, or other commercial document or instrument and no course of dealing shall be effective to modify any of the terms of this Agreement.

	
33.

	
Notices.  All notices to be given as required in this Agreement shall be in writing and may be delivered personally, or mailed either by a reputable overnight carrier with signature receipt or certified mail, postage prepaid to the Parties at the addresses set forth below or at such other address as either Party may provide by written notice to the other Party in accordance with the provisions of this Section 33.  Any such notice shall be effective: (i) on the date sent, if delivered personally or by facsimile (receipt of which is confirmed); (ii) the date after delivery if sent by overnight carrier; or (iii) on the date received if sent by certified mail.  Notices for the Parties shall be sent to:

 

If to Discovery:

Discovery Laboratories, Inc.

2600 Kelly Road

Suite 100

Warrington, PA  18976-3646

Attention: [***]

FAX: [***]

And with a required copy to:

Discovery Laboratories, Inc.

2600 Kelly Road

Suite 100

Warrington, PA  18976-3646

Attention:  [***]

	
  

	
FAX: [***]

If to LACEY:

Lacey Manufacturing Company

1146 Barnum Avenue,

Bridgeport, Connecticut 06610

Attn: [***]

FAX: [***]

 

  

Page 16 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

	
34.

	
Entire Agreement.  This Agreement and the CDA contain the entire understanding between the Parties with respect to development of the AFECTAIR Devices and the Project.  Any representation, promise, or condition that is not incorporated herein shall not be binding upon either Party.

	
35.

	
Assignment.  Neither this Agreement nor any rights or obligations hereunder may be assigned, transferred, delegated, pledged, hypothecated, or encumbered by either Party without the prior written consent of the other Party hereto, except that the rights and obligations of either Party may be assigned to any entity that acquires substantially all of the relevant assets of the assigning Party, unless the acquisition is made by a direct competitor of the other Party, in which case either Party may terminate this Agreement.  The sale of a controlling interest in the equity securities of a Party shall not be deemed an assignment hereunder.

	
36.

	
No Waiver.  Neither Party hereto shall be deemed to have waived the protection of any provision hereof, not its right to enforce the same upon a breach or subsequent breach thereof, unless such waiver shall be in writing and executed in a manner similar to the execution of this Agreement.

	
37.

	
Counterparts.  This Agreement may be executed in multiple counterparts, but all such counterpart documents shall constitute but one, single agreement.

	
38.

	
Severability.  In the event that one or more provisions of this Agreement is held to be invalid, illegal or unenforceable for any reason, the same shall not affect any other provision of this Agreement, but this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

	
39.

	
This Agreement is intended solely for the benefit of the executing Parties.  No other person or entity shall have any rights under or in connection with this Agreement.

In witness whereof, authorized representatives of the Parties have executed this Agreement.

 

	
DISCOVERY LABORATORIES, INC.

	 
	 	 
	
By:   W. Thomas Amick, Chief Executive Officer

	 
	 	 
	Signature:  /s/ W. Thomas Amick      Date     2.2.2012	 
	 	 
	LACEY MANUFACTURING COMPANY, A DIVISION OF PRECISION ENGINEERED PRODUCTS, LLC	 
	 	 
	
By:   Kenneth Lisk,  President

	 
	Signature: Kenneth Lisk                      Date     2.2.2012	 

  

Page 17 of 24

[***] Denotes Material is Subject to a Confidential Treatment Request

  

APPENDIX A

AFECTAIR® DEVICES PROGRAM

 

LACEY SCOPE OF WORK

 

	
  

	
·

	
PRODUCTS

 

	
  

	
o

	
 AFECTAIR Small- Adapter only for infants

 

	
  

	
o

	
 AFECTAIR Large- Adapter only for children and adults

 

	
  

	
o

	
AFECTAIR DUO Small- Adapter, tee, tubing for infants

 

	
  

	
o

	
AFECTAIR DUO Large- Adapter, tee, tubing for children and adults

 

	
  

	
·

	
MANUFACTURING

 

[***]

 

	
  

	
·

	
REGULATORY/QA

 

[***]

 

	
·

	
OTHER

 

[***]

 

  

A-1

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

 AFECTAIR Device Components

 

[***]

 

  

A-2

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

 AFECTAIR Duo Device Components

 

[***]

 

 

Terms and Conditions of Payment

 

See Appendix A-1

 

Equipment to be Purchased by LACEY

 

 See Appendix A-2

 

  

A-3

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

Appendix A-1

 

TERMS AND CONDITIONS

 

[***]

  

A-4

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

Appendix A-2

INITIAL EQUIPMENT

 

[***]

  

A-5

[***] Denotes Material is Subject to a Confidential Treatment Request

  

 

Appendix A-2

[Form of] Equipment Addendum

[To be executed and appended to each Equipment Purchase Order]

Addendum to Purchase Order between Discovery Laboratories, Inc. (“DSCO”) and Lacey Manufacturing Company (“LACEY”).

Each of DSCO and LACEY agree that:

[***]

 

	Discovery Laboratories, Inc.	 	Lacey Manufacturing Company, LLC	 
	 	 	 	 	 	 
	By:	 	 	By:	 	 
	 	 	 	 	 	 
	Name: 	 	 	Name:	 	 
	 	 	 	 	 	 
	Title: 	 	 	Title:	 	 

 

                                                                                     

A-6

[***] Denotes Material is Subject to a Confidential Treatment Requestex10_2.htm

EXHIBIT 10.2

 

DISCOVERY LABORATORIES, INC.

2011 LONG-TERM INCENTIVE PLAN

STOCK OPTION AGREEMENT

Employee

 

RECITALS

A.            The Board has adopted the Discovery Laboratories, Inc. 2011 Long-Term Incentive Plan (the “Plan”) for the purpose of encouraging selected Employees, directors and consultants of the Company and its Subsidiaries to acquire a proprietary interest in the growth and performance of the Company, to generate an increased incentive to contribute to the Company’s future success and prosperity, thus enhancing the value of the Company for the benefit of its stockholders, and to enhance the ability of the Company and its Subsidiaries to attract and retain exceptionally qualified individuals upon whom, in large measure, the sustained progress, growth and profitability of the Company depend.

 

B.            Participant is an Employee who will render valuable Services to the Company (or Subsidiary), and this Award Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company's grant of an option to Participant.

 

C.            All capitalized terms in this Stock Option Agreement (“Award Agreement”) shall have the meaning assigned to them in the Plan.  For convenience, relevant portions of certain of the Plan definitions and certain additional definitions relating to this Award Agreement are included in the Appendix.  This Award Agreement, including the Notice of Grant, is subject to the terms of the Plan, which are incorporated in this Award Agreement by reference.  If there is a conflict between the terms of the Plan and this Award Agreement or the Notice of Grant, the terms of the Plan shall prevail.

 

NOW, THEREFORE, it is hereby agreed as follows:

1.           Award of Option.  The Company hereby grants to Participant, as of the Award Date, an option to purchase up to the number of Option Shares specified in the Notice of Grant. The Option Shares shall be purchasable from time to time as specified in Paragraph 4 during the option term specified in Paragraph 2 at the Option Price set forth in the Notice of Grant.

 

2.           Option Term.  This option shall have a term commencing on the Award Date and ending on the Expiration Date set forth in the Notice of Grant.  The option shall expire at the close of business on the Expiration Date, unless sooner terminated in accordance with Paragraph 5 or 6.

 

3.           Limited Transferability.  The option granted under this Award Agreement shall not be assignable, alienable, saleable, or transferable by Participant other than by will or by the laws of descent and distribution; provided, however, that, if a procedure shall be adopted by the Committee at any time, Participant may designate a beneficiary or beneficiaries to exercise the rights of Participant with respect to this option upon Participant’s death.  The option granted under this Award Agreement shall be exercisable during Participant’s lifetime only by Participant or, if permissible under applicable law, by Participant’s guardian or legal representative.  This option may not be pledged, alienated, attached, or otherwise encumbered, and any purported pledge, alienation, attachment, or encumbrance thereof shall be void and unenforceable against the Company or any affiliate of the Company.  Notwithstanding the foregoing, if this option is designated a Non-Qualified Stock Option in the Notice of Grant, then this option may, in connection with Participant's estate plan, be assigned, in whole or in part, during Participant's lifetime to one or more members of Participant's immediate family or to a trust established for the exclusive benefit of one or more such family members.  The assigned portion shall be exercisable only by the person or persons who acquire a proprietary interest in the option pursuant to such assignment.  The terms applicable to the assigned portion shall be the same as those in effect for this option immediately prior to such assignment and shall be set forth in such documents issued to the assignee as the Committee may deem appropriate.

 

  

  

  

 

4.           Dates of Exercise.  This option shall vest and become exercisable for the Option Shares in one or more installments as specified in the Notice of Grant.  As the option becomes exercisable for such installments, those installments shall accumulate, and the option shall remain exercisable for the accumulated installments until the Expiration Date or sooner termination of the option term under Paragraph 5 or 6.

 

5.           Termination of Service.  The option term and this option shall expire and cease to be exercisable prior to the Expiration Date should any of the following provisions become applicable:

 

  (a)           If Participant's Service is terminated for any reason other than death, Disability or for Cause, then Participant shall have the right to exercise, in whole or in part, that portion of this option that was vested and exercisable on the date of termination of Service until the earlier of (i) three (3) months after termination of Service or (ii) the Expiration Date; and, to the extent that any portion of this option was not exercisable on the date of termination of Service, it will immediately terminate.

 

  (b)           If Participant's Service is terminated on account of death or Disability, then Participant or Participant's Beneficiary (as applicable) shall have the right to exercise, in whole or in part, that portion of this option that was vested and exercisable on the date of termination of Service until the earlier of (i) one (1) year after Participant’s termination of Service or (ii) the Expiration Date; and, to the extent that any portion of this option was not exercisable on the date of termination of Service, it will immediately terminate.

 

  (c)           If Participant's Service is terminated for Cause or if Participant shall breach any post-Service duties to the Company or any post-Service covenants or agreements, including any confidentiality or non-competition and non-solicitation agreement, any unexercised portion of this option shall terminate immediately. Solely for the purposes of this Award Agreement, notwithstanding any notice period or cure period provided in any employment or other applicable agreement, if Participant is terminated for Cause, the date of termination shall be deemed to be the date on which the Company issues a notice of termination to Participant (subject to any right that the Participant may have to cure).  The right to exercise any vested and unexercised portion of this option shall be suspended during any such notice or cure period.  Should the Company revoke any notice of termination based on Participant’s satisfactory cure under an employment or other applicable agreement, the Committee may reinstate the right to exercise this option under the original terms of this Award Agreement.

 

6.           Special Acceleration of Option.  Except as otherwise expressly provided in a Participant’s employment or other applicable agreement, which shall supersede the provisions of this Paragraph 6 solely to the extent that the rights and privileges under such agreement, as determined by the Committee, in its discretion, are not reasonably likely to significantly diminish the rights and benefits that would otherwise be provided under this paragraph 6:

 

  

2

  

 

  (a)           In the event of a Change in Control, vesting under this option shall automatically accelerate so that, immediately prior to the effective date of the Change in Control, but subject to the occurrence of the Change in Control, this option shall become exercisable with respect to the total number of Option Shares at the time subject to this option and may be exercised for any or all of those Option Shares.  However, vesting under this option shall not so accelerate if and to the extent: (i) this option is, in connection with the Change in Control, either to be assumed by the successor corporation (or parent thereof) or to be replaced with a comparable option to purchase shares of the capital stock of the successor corporation (or parent thereof),  or (ii) this option is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing on any unvested Option Shares at the time of the Change in Control (the excess of the Fair Market Value of those Option Shares over the aggregate Option Price payable for such Option Shares) and provides for subsequent pay-out in accordance with the same option vesting schedule set forth in the Notice of Grant.  The determination of comparability under clause (i) above shall be made by the Committee, and its determination shall be final, binding and conclusive.  Notwithstanding the foregoing, the Committee shall have the discretion, exercisable at any time during the option term, to provide for the automatic acceleration of all or a portion of this option upon the occurrence of a Change in Control, whether or not this option is to be assumed or replaced in the Change in Control.

 

  (b)           Upon the occurrence of the termination of Participant's Service by reason of an Involuntary Termination (as defined below) within eighteen (18) months following the effective date of a Change in Control, vesting under this option shall accelerate automatically and this option shall become exercisable with respect to the total number of Option Shares at the time subject to this option and shall remain exercisable until the earlier of (i) one year after the effective date of the Involuntary Termination, or (ii) the Expiration Date.  Involuntary Termination shall mean the termination of the Service of any individual which occurs by reason of:

 

   (i)            such individual’s involuntary dismissal or discharge by the Company for reasons other than Cause, or

 

  (ii)           such individual’s voluntary resignation following (A) a change in his or her position with the Company (or Subsidiary employing such individual) which materially reduces such individual’s duties and responsibilities or the level of management to which such individual reports, (B) a reduction in such individual’s level of compensation (including base salary, fringe benefits and target bonus under any corporate performance-based bonus or incentive programs) by more than fifteen percent (15%) or (C) a relocation of such individual’s place of employment by more than fifty (50) miles, and farther from the Participant’s residence than prior to the relocation; provided and only if such change, reduction or relocation is effected by the Company without such individual’s consent; provided that such voluntary resignation shall not be an Involuntary Termination unless the Participant gives the Company written notice of the Participant’s intent to resign as a result of the existence of a specified condition described in (A), (B) or (C) within 90 days of the initial existence of such condition, provides the Company 30 days to cure such condition, and actually resigns no more than 10 days after the lapse of such 30-day cure period if the condition is not cured.

 

  (c)           This Award Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

 

7.           Repurchase Right.  If at any time Participant’s Service is terminated for Cause or if Participant shall breach any covenants set forth in any written agreement between Participant and the Company, the Company may, in its discretion, for a period of one (1) year after the termination for Cause or upon the actual discovery by the Company of the breach, whether or not within such 1-year period, as the case may be, and upon 10 (ten) days’ notice to Participant, (i) repurchase all or any portion of any Shares acquired by Participant upon Participant’s exercise of this option, and/or (ii) require Participant to repay to the Company the amount of any profits realized by Participant upon the sale or other disposition during the preceding three (3) years of any Shares acquired by Participant upon Participant’s exercise of this option.  The purchase price for any Shares repurchased by the Company pursuant to clause (i) of this Paragraph 7 shall be the lesser of the price paid by Participant to acquire such Shares and the Fair Market Value thereof on the date of such repurchase by the Company.  In addition, the Company shall have repurchase rights in accordance with the terms of any repurchase policy as may be in effect from time to time.

 

  

3

  

 

8.           Adjustment in Option Shares.  Should any change be made to the Shares of the Company by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Shares as a class without the Company's receipt of consideration, appropriate adjustments shall be made to (i) the total number and/or class of securities subject to this option and (ii) the Option Price in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.

 

9.           Stockholder Rights.  The holder of this option shall not have any stockholder rights with respect to the Option Shares until such person shall have exercised the option, paid the Option Price and become a holder of record of the purchased Shares.

 

10.           Manner of Exercising Option.

 

  (a)           In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable, Participant (or any other person or persons exercising the option) must take the following actions:

 

  (i)            Execute and deliver to the Company a Notice of Exercise for the Option Shares for which the option is exercised.

 

  (ii)           Pay the aggregate Option Price for the purchased Shares in one or more of the following forms:

 

  (A)           cash or check made payable to the Company;

 

  (B)           Shares held by Participant (or any other person or persons exercising the option) for the requisite period necessary to avoid a charge to the Company's earnings for financial reporting purposes and valued at Fair Market Value on the Exercise Date; or

 

  (C)           provided that no restrictions against trading in the Shares are then in effect, as contemplated by Paragraph 11, (I) through a “net exercise” arrangement to the extent permitted by applicable law, or (II) through a special sale and remittance procedure pursuant to which Participant (or any other person or persons exercising the option) shall concurrently provide irrevocable instructions (x) to a Company-approved brokerage firm to effect the immediate sale of the purchased Shares and remit to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate Option Price payable for the purchased Shares plus all applicable income and employment taxes required to be withheld by the Company by reason of such exercise and (y) to the Company to deliver the certificates for or other evidence of the purchased Shares directly to such brokerage firm in order to complete the sale.

 

Except to the extent the net exercise or the sale and remittance procedure is utilized in connection with the option exercise, payment of the Option Price must accompany the Notice of Exercise delivered to the Company in connection with the option exercise.

 

  

4

  

 

   (iii)           Furnish to the Company appropriate documentation that the person or persons exercising the option (if other than Participant) have the right to exercise this option.

 

  (iv)          Make appropriate arrangements with the Company (or Parent or Subsidiary employing or retaining Participant) for the satisfaction of all income and employment tax withholding requirements applicable to the option exercise.

 

  (b)           As soon as practical after the Exercise Date, the Company shall deliver to or on behalf of Participant (or any other person or persons exercising this option) a certificate for the purchased Option Shares, with the appropriate legends affixed thereto, shall effect book-entry registration in the Participant’s (or such other person’s) name.

 

 (c)           In no event may this option be exercised for any fractional shares.

 

11.         Compliance with Laws and Regulations.

 

  (a)           The exercise of this option and the delivery of the Shares upon such exercise shall be subject to compliance by the Company and Participant with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange on which the Shares may be listed for trading at the time of such exercise and delivery.

 

  (b)           The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance or delivery and sale of any Shares pursuant to this option shall relieve the Company of any liability with respect to the non-issuance, non-delivery or sale of the Shares as to which such approval shall not have been obtained.  The Company, however, shall use its best efforts to obtain all such approvals.

 

12.         Successors and Assigns.  Except to the extent otherwise provided in Paragraphs 3 and 6, the provisions of this Award Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant and Participant's assigns and Beneficiaries.

 

13.         Notices.  Any notice required to be given or delivered to the Company under the terms of this Award Agreement shall be in writing and addressed to the Company at its principal corporate offices.  Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated below Participant's signature line on the Notice of Grant.  All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.

 

14.         Construction.  This Award Agreement and the option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan.  All decisions of the Committee with respect to any question or issue arising under the Plan or this Award Agreement shall be conclusive and binding on all persons having an interest in this option.

 

15.         Governing Law.  The interpretation, performance and enforcement of this Award Agreement shall be governed by the laws of the State of Delaware without resort to that State's conflict-of-laws rules.

 

  

5

  

 

16.           Excess Shares.  If the Option Shares covered by this Award Agreement exceed, as of the Award Date, the number of Shares which may without stockholder approval be delivered under the Plan, then this option shall be void with respect to those excess Shares, unless stockholder approval of an amendment sufficiently increasing the number of Shares issuable under the Plan is obtained in accordance with the provisions of the Plan.

 

17.         Additional Terms Applicable to an Incentive Stock Option.  The terms of any Incentive Stock Option granted under the Plan shall be designed to comply in all respects with the provisions of Section 422 of the Code, or any successor provision thereto, and any regulations promulgated thereunder. Notwithstanding anything in this Paragraph 17 to the contrary, Options designated as Incentive Stock Options shall not be eligible for treatment under the Code as Incentive Stock Options (and will be deemed to be Non-Qualified Stock Options) to the extent that either (1) the aggregate Fair Market Value of Shares (determined as of the time of grant) with respect to which such Options are exercisable for the first time by Participant during any calendar year (under all plans of the Company and any Subsidiary) exceeds $100,000, taking Options into account in the order in which they were granted, or (2) such Options otherwise remain exercisable but are not exercised within three (3) months of termination of employment (or such other period of time provided in Section 422 of the Code).

 

18.         Leave of Absence.  The following provisions shall apply upon Participant's commencement of an authorized leave of absence:

 

  (a)           The exercise schedule in effect under the Notice of Grant shall be frozen as of the first day of the authorized leave, and this option shall not become exercisable for any additional installments of the Option Shares during the period Participant remains on such leave.

 

  (b)           Should Participant resume active Employee status within sixty (60) days after the start date of the authorized leave, Participant shall, for purposes of the exercise schedule set forth in the Notice of Grant, receive Service credit for the entire period of such leave.  If Participant does not resume active Employee status within such sixty (60)-day period, then no Service credit shall be given for the period of such leave.

 

  (c)           If this option is designated as an Incentive Stock Option in the Notice of Grant, then the following additional provision shall apply:

 

  (i)           If the leave of absence continues for more than ninety (90) days, then this option shall automatically convert to a Non-Qualified Stock Option at the end of the three (3)-month period measured from the ninety-first (91st) day of such leave, unless Participant's reemployment rights are guaranteed by statute or by written agreement.  Following any such conversion of this option, all subsequent exercises of this option, whether effected before or after Participant's return to active Employee status, shall result in an immediate taxable event, and the Company shall be required to collect from Participant the income and employment withholding taxes applicable to such exercise.

 

  (ii)           In no event shall this option become exercisable for any additional Option Shares or otherwise remain outstanding if Participant does not resume Employee status prior to the Expiration Date.

 

  

6

  

 

This page intentionally left blank.

 

 

  

  

  

EXHIBIT I

NOTICE OF EXERCISE

 

I hereby notify Discovery Laboratories, Inc. (the "Company") that I elect to purchase ________ Shares (the "Purchased Shares") at the Option Price of $ _________ per share pursuant to that certain option (the "Option") granted to me under the Company's 2011 Long-Term Incentive Plan on ______________, ____.

Concurrently with the delivery of this Exercise Notice to the Company, I shall hereby pay to the Company the Option Price for the Purchased Shares in accordance with the provisions of my Notice of Grant and Award Agreement with the Company (or other documents) evidencing the Option and shall deliver whatever additional documents may be required by such agreement as a condition for exercise.  Alternatively, if I am eligible I may utilize the net exercise or the special broker-dealer sale and remittance procedure specified in my agreement to effect payment of the Option Price.

	 	 	 	 
	Date	 	 
	 	 	 
	 	 	Participant
	 	 	 
	 	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	Print name in exact manner it is to appear on the stock certificate: 	 	 
	 	 	 
	Address to which certificate is to be sent, if different from address above: 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number: 	 	 
	 	 	 
	Employee Number:  	 	 

 

  

  

  

                                                                           

This page intentionally left blank.

 

 

  

  

  

 

APPENDIX

The following definitions shall be in effect under the Award Agreement:

Award Date shall mean the effective date of grant of the option as specified in the Notice of Grant.

Award Agreement shall mean this Stock Option Agreement and the associated Notice of Grant pursuant to which the Option is granted.

Beneficiary shall mean, in the event the Committee implements a beneficiary designation procedure, the person designated by Participant, pursuant to such procedure, to succeed to such person's rights under any outstanding awards held by Participant at the time of death.  In the absence of such procedure or designation, the Beneficiary shall be Participant’s personal representative or the person or persons to whom this Option is transferred by will or the laws of descent and distribution.

Board shall mean the Company's Board of Directors.

Cause, with respect to any Employee or Consultant of the Company or a Subsidiary, shall have the meaning set forth in such person’s employment, consulting or other applicable agreement, or, in the absence of any such agreement or if such term is not defined in any such agreement, shall mean any one or more of the following, as determined by the Committee:

 

	
  

	
(i)

	
willful misconduct or gross negligence in the performance of such person’s duties;

	
  

	
(ii)

	
willful and continued failure or refusal to perform satisfactorily any duties reasonably requested in the course of such person’s employment by, or service to, the Company (other than a failure resulting from such person’s disability); or

	
  

	
(iii)

	
fraudulent, dishonest or other improper conduct engaged in by such person that causes, or has the potential to cause, harm to the Company or any of its Subsidiaries, or its or their business or reputation, including, without limitation, such person’s violation of any policies of the Company applicable to the such person, such person’s violation of laws, rules or regulations applicable to such person, criminal activity, habitual drunkenness or use of illegal drugs.

Change in Control shall have the meaning, if any, set forth in a Participant’s employment, consulting or other applicable agreement, or, if such term is not defined in any such agreement, shall mean the first to occur of the following:

	
  

	
(i)

	
any Person (other than (1) the Company, or (2) any trustee or other fiduciary under an employee benefit plan of the Company), is or becomes the beneficial owner (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of securities of the Participant’s Employer (as defined below) by reason of having acquired such securities during the 12-month period ending on the date of the most recent acquisition (not including any securities acquired directly from the Company or its Affiliates) representing thirty percent (30%) or more of the total voting power of the Participant’s Employer’s then outstanding voting securities;

 

  

  

  

 

	
  

	
(ii)

	
the majority of members of the board of directors of the Participant’s Employer is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the board of directors of the Participant’s Employer before the date of the appointment;

	
  

	
(iii)

	
there is consummated a merger or consolidation of the Participant’s Employer or any subsidiary thereof with any other corporation or other entity, resulting in a change described in clauses (i), (ii), (iv) or (v) of this definition, other than (1) a merger or consolidation that would result in the voting securities of the Participant’s Employer outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or parent entity) more than sixty percent (60%) of the total voting power of the voting securities of the Participant’s Employer or such surviving or parent entity outstanding immediately after such merger or consolidation or (2) a merger or consolidation effected to implement a recapitalization of the Company or the Participant’s Employer (or similar transaction) in which no Person, directly or indirectly, acquired forty percent (40%) or more of the total voting power of the then outstanding securities of the Participant’s Employer (not including any securities acquired directly from the Company or its Affiliates);

	
  

	
(iv)

	
a liquidation of the Participant’s Employer involving the sale to any Person of at least forty percent (40%) of the total gross fair market value of all of the assets of the Participant’s Employer immediately before the liquidation; or

	
  

	
(v)

	
the sale or disposition by the Participant’s Employer or any direct or indirect subsidiary of the Participant’s Employer to any Person (other than any Subsidiary) of assets that have a total fair market value equal to forty percent (40%) or more of the total gross fair market value of all of the assets of the Participant’s Employer and its subsidiaries (taken as a whole) immediately before such sale or disposition (or any transaction or related series of transactions having a similar effect), other than a sale or disposition by the Company or the Participant’s Employer or any direct or indirect subsidiary of either to an entity at least sixty percent (60%) of the total voting power of the voting securities of which is beneficially owned by Stockholders of the Company or the Participant’s Employer in substantially the same proportions as their beneficial ownership of the Company or the Participant’s Employer immediately prior to such sale.

	
For purposes of this definition, “Participant’s Employer” shall mean (1) the Company or a Subsidiary corporation for which the Participant directly provides services or (2) a corporation that is a majority stockholder of the Company or a Subsidiary, or any corporation in a chain of corporations each of which is a majority stockholder of another corporation in the chain, ending with the corporation described in (1).

Code shall mean the Internal Revenue Code of 1986, as a mended from time to time.  A reference to a section of the Code shall be deemed to include any successor sections of the Code.

Committee shall mean a committee of the Board, acting in accordance with the provisions of Section 3 of the Plan, designated by the Board to administer the Plan.  To the extent the Committee has delegated authority, the term “Committee” shall refer to such delegate.

Company shall mean Discovery Laboratories, Inc. and any Subsidiary to which Participant may render Services.

  

  

  

 

Disability for each respective Participant shall have the meaning set forth in the Participant’s employment agreement; provided, that if such term is not defined in any such agreement then “Disability” shall mean (i) with respect to any Incentive Stock Option, a permanent and total disability, within the meaning of Section 22(e)(3) of the Code, and (ii) for any other purpose, “disability” as defined in the Company’s long term disability program applicable to the Participant (or that would be applicable to the Participant if the Participant elected coverage).

Employee shall mean any person treated as an employee (including officers and directors) in the records of the Company or any Subsidiary and who is subject to the control and direction of the Company or any Subsidiary with regard to both the work to be performed and the manner and method of performance.

 

Exercise Date shall mean the date on which the option shall have been exercised in accordance with Paragraph 10 of this Award Agreement.

Expiration Date shall mean the date on which the option expires as specified in the Notice of Grant.

Fair Market Value of a Share on any date of reference shall be determined by the Committee, in its sole discretion, and may be different for different purposes.  Unless the Committee determines otherwise,

	
  

	
(i)

	
if the Shares are listed or admitted for trading on any United States national securities exchange, or if actual transactions are otherwise reported on a consolidated transaction reporting system, the last reported sale price of a Share on such exchange or reporting system, as reported in any newspaper of general circulation, or

	
  

	
(ii)

	
if clause (i) is not applicable, the mean of the high bid and low asked quotations for a Share as reported by the National Quotation Bureau, Incorporated if at least two securities dealers have inserted both bid and asked quotations for the Shares on at least five of the 10 preceding trading days; or

	
  

	
(iii)

	
if clauses (i) and (ii) above are not applicable to the Company (e.g., if the Shares are not then publicly traded or quoted), then the “Fair Market Value” of a Share shall be the fair market value (i.e., the price at which a willing seller would sell a Share to a willing buyer when neither is acting under compulsion and when both have reasonable knowledge of all relevant facts) of a Share on such date as the Committee in its sole and absolute discretion shall determine in a fair and uniform manner.

Incentive Stock Option shall mean an option that is intended to meet the requirements of Section 422 of the Code.

Non-Qualified Stock Option shall mean an option granted under this Award Agreement that is not intended to be an Incentive Stock Option.

Notice of Exercise shall mean the notice of exercise in the form attached hereto as Exhibit I.

Notice of Grant shall mean the Notice of Grant of Stock Options accompanying the Award Agreement, pursuant to which Participant has been informed of the basic terms of the option evidenced hereby.

  

  

  

 

Option Price shall mean the purchase price payable for Option Shares under this option, as specified in the Notice of Grant.

Option Shares shall mean the number of Shares subject to the option as specified in the Notice of Grant.

Participant shall mean the person to whom the option is granted as specified in the Notice of Grant.

Performance Criteria shall mean any quantitative and/or qualitative measures, as determined by the Committee, which may be used to measure the level of performance of the Company or any individual Participant during a Performance Period, including any Qualifying Performance Criteria.

[Delete unless option is performance-vested]

Performance Period shall mean any period as determined by the Committee in its sole discretion.

[Delete unless option is performance-vested]

Plan shall mean the Company's 2011 Long-Term Incentive Plan, as amended from time to time.

Qualifying Performance Criteria shall mean one or more of the following performance criteria, either individually, alternatively or in any combination, applied to either the Company as a whole or to a business unit or related Subsidiary, and measured either annually or cumulatively over a period of years, on an absolute basis or relative to a pre-established target, to a previous year’s results or to a designated comparison group, in each case as specified by the Committee in the Award Agreement: achieving specified milestones in the discovery and development, commercialization or manufacturing of one or more of the Company product candidates, obtaining debt or equity financing, achieving personal management objectives, achieving sales, revenue, net income (before or after taxes), net earnings, earnings per share, return on total capital, return on equity, cash flow, cash flow from operations, operating profit and/or margin rate targets, subject to adjustment by the Committee to remove the effect of charges for restructurings, discontinued operations, extraordinary items and all items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence, related to the disposal of a segment or a business, or related to a change in accounting principle or otherwise.

[Delete unless option is performance-vested]

Service shall mean Participant's performance of services for the Company (or any Subsidiary) in the capacity of Employee, non-employee director or consultant.

Shares shall mean the common shares of the Company and such other securities as may become the subject of this Option pursuant to an adjustment made under Section 4(b) of the Plan.

Subsidiary shall mean a subsidiary company as defined in Section 424(f) of the Code (with the Company being treated as the employer corporation for purposes of this definition).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]